Definitive Contract 75N93024C00069
Award Date 9/16/24
Potential Completion Date 9/15/29
Potential Value $9.9M
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Menands, NY 12204, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
18
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $10,279,321.93 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to Health Research, Inc. (HRI), a non-profit organization. The contract is for "LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION" and has a completion date of September 15, 2025. The contract is a cost-no-fee arrangement and was not set aside for any specific business...
- This is a $2,999,999 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Design-Zyme LLC, a small business, under the SBIR (Small Business Innovation Research) program. The contract is for the development of covalently bound hyaluronic acid as an adjuvant for a multivalent Lyme disease vaccine. This contract was competitively awarded under the SBIR program, which aims to stimulate...
- The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) awarded a $5,455,891.00 definitive contract to the La Jolla Institute for Immunology (LJI), a non-profit research institute, to conduct research on the identification and characterization of T cell epitopes from bacterial pathogens causing pneumonia. The contract, which is not set-aside, has a completion date of September 29, 2029. LJI will perform specialized research services to support...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $37.25 million Cost-No-Fee definitive contract to the La Jolla Institute for Immunology (LJI) for continuation of the Immune Epitope and Analysis Program (IEDB). This contract, which runs through March 2026, supports LJI's mission to maintain and enhance a comprehensive database and analysis resource for immune epitope research. The IEDB serves as a critical scientific resource for the immunological research community,...
- This is a task order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a not-for-profit contract research organization. The task order, titled "PRE-CLINICAL MODELS OF INFECTIOUS DISEASES TASK ORDER B07", is part of NIAID's Preclinical Models of Infectious Diseases contract vehicle, which provides...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID) to the La Jolla Institute for Immunology (LJI), a non-profit research institute. The $6,153,015 definitive contract, awarded on March 31, 2004, is for a "Large Scale Antibody and T Cell Epitope Discovery Program" with a period of performance through September 30, 2009. The contract is a cost-no-fee type, without any set-aside designation. LJI is an experienced federal contractor...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $716,374 delivery order contract to Lovelace Biomedical Research Institute. Under the terms of the firm fixed price contract, Lovelace Biomedical Research Institute will conduct a Good Laboratory Practice repeat dose toxicology study for BPL-24910 in support of the Comprehensive and Rapid Response for NIAID Research Programs major program code. Performance...
- The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $2,000 firm fixed price delivery order against an unspecified contract vehicle to Lovelace Biomedical Research Institute. The delivery order is for comprehensive and rapid response services to support NIAID's research programs over a one year period from September 2021 through August 2022. The place of performance will be in Bethesda, Maryland. No set aside designation or subcontractors were...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,645,425.63 definitive contract to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI) to conduct the "Natural History of Andenovirus and Related Disease in Immuncomporised Pediatric Patients" project. This contract, which does not have a set-aside designation, was issued under LBERI's parent company Lovelace Biomedical Research Institute, an expert in preclinical research services across...
- The Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $8,300,733.00 cost-plus-fixed-fee delivery order contract to Leidos Biomedical Research, Inc., a subsidiary of Leidos Holdings, Inc. The contract is for NIAID DIR (Division of Intramural Research) operational support services and has a completion date of September 12, 2020. This award is not designated as a set-aside contract. Leidos...